A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
Clinical trial NCT05133882 · RECRUITING
Trial details
- NCT number
- NCT05133882
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-31
- Primary completion
- 2027-12-31
- Enrollment
- 133
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.